Search results
Showing 796 to 810 of 2107 results for technology appraisal
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.
Tildrakizumab for treating active psoriatic arthritis [ID6724]
Awaiting development Reference number: GID-TA11807 Expected publication date: TBC
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.
An approximate guide to the timings for the development of a piece of HealthTech guidance.
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
Membership details, terms of reference, future meeting dates and past meeting minutes for our diagnostics advisory committee.
Membership details, terms of reference, future meeting dates and past meeting minutes for our diagnostics advisory committee.
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.
Over the next year, our prioritisation decisions will be shaped by the government’s strategic direction for health and life sciences, and by the needs of the NHS, local systems and the people who use services.
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
In development Reference number: GID-TA11565 Expected publication date: 18 November 2026